Kiniksa Pharmaceuticals, Ltd.
KNSA · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 9.30 | 0.28 | -0.24 | 1.21 |
| FCF Yield | 1.15% | 1.37% | 1.38% | 1.30% |
| EV / EBITDA | 97.78 | 90.15 | 107.68 | -75.80 |
| Quality | ||||
| ROIC | 2.76% | 2.88% | 1.44% | -2.10% |
| Gross Margin | 53.78% | 54.70% | 55.25% | 46.00% |
| Cash Conversion Ratio | 1.83 | 1.58 | 2.61 | -2.11 |
| Growth | ||||
| Revenue 3-Year CAGR | 33.96% | 23.53% | 26.74% | 24.34% |
| Free Cash Flow Growth | 18.20% | 25.65% | 19.64% | 930.81% |
| Safety | ||||
| Net Debt / EBITDA | -6.00 | -8.88 | -10.81 | 10.48 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 2.02 | 1.47 | 2.79 | 2.51 |
| Cash Conversion Cycle | 63.70 | 68.02 | 55.49 | 63.73 |